Be Prepared to Dispense Alternatives to Usual COVID-19 Meds

Shortages of tocilizumab (Actemra) mean you'll see more orders for other COVID-19 treatments.

Tocilizumab has been the go-to add-on to steroids (dexamethasone, etc) for COVID-19. It's because this "IL-6 inhibitor" has the strongest evidence for reducing mortality.

But tocilizumab supplies are low. And it may need to be reserved for other uses where tocilizumab is the only treatment.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote